Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | PDE5A | O76074 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CCND3 | P30281 | 4/20 | 0.46 |
| ▸ | CDK4 | P11802 | 3/20 | 0.46 |
| ▸ | CCND1 | P24385 | 3/20 | 0.46 |
| ▸ | CCND2 | P30279 | 3/20 | 0.46 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 3/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.45 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16285676 | 0.90 | KMT2A (0.57) | MEN1HPGDKMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL16285698 | 0.89 | CDK4 (0.48) | L3MBTL1CCND3CDK4CCND1CCND2 | |
| SCHEMBL16285697 | 0.88 | MAPT (0.51) | HPGDSMN1; SMN2L3MBTL1ALDH1A1CCND3 | |
| SCHEMBL16285681 | 0.88 | FYN (0.56) | CCND3CDK4CCND1CCND2NPC1 | |
| SCHEMBL16285674 | 0.86 | CDK4 (0.50) | PDE5ACCND3CDK4CCND1CCND2 | |
| SCHEMBL16285675 | 0.83 | EGFR (0.49) | CCND3CDK4CCND1CCND2KDM1A | |
| SCHEMBL16285677 | 0.83 | JAK2 (0.49) | KMT2AL3MBTL1ALDH1A1CCND3CDK4 | |
| SCHEMBL16285709 | 0.82 | HTR1A (0.46) | CCND3CDK4CCND1CCND2NPC1 | |
| SCHEMBL16285670 | 0.82 | NTRK1 (0.50) | HPGDKMT2ACCND3CDK4CCND1 | |
| SCHEMBL16285708 | 0.81 | CDK4 (0.47) | CCND3CDK4CCND1CCND2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | GRIN2A, GRIN2C, GRIN3A | MEN1 4872/4885HPGD 2207/4885KMT2A 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.